logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASH 2019 – Waldenstrom’s macroglobulinemia: idelalisib+obinutuzumab shows activity

Interim analysis of phase 2 trial to evaluate chemotherapy-free combination treatment.